NASDAQ / LIVE COMPANY INTELLIGENCE

Madrigal Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERMDGL
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / MDGL COVERAGE

What’s moving Madrigal Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)

BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)

The story matters when it changes Madrigal Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

The story matters when it changes Madrigal Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

The story matters when it changes Madrigal Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript

Investors are testing whether Madrigal Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Madrigal Pharmaceuticals, Inc. to Present at 46th Annual Global Goldman Sachs Health Care Conference on June 11, 2025

Madrigal Pharmaceuticals, Inc. to Present at 46th Annual Global Goldman Sachs Health Care Conference on June 11, 2025

The story matters when it changes Madrigal Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest MDGL filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-30 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-19 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-30 · Period 2026-07-30SEC ↗8-KMaterial company eventFiled 2026-06-17 · Period 2026-06-16SEC ↗8-KMaterial company eventFiled 2026-05-06 · Period 2026-05-06SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-17SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-29SEC ↗
EARNINGS / QUARTERLY TRACKER

Madrigal Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.